Literature DB >> 24477622

Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.

Kathleen Dorris1, Matthew Sobo, Arzu Onar-Thomas, Eshini Panditharatna, Charles B Stevenson, Sharon L Gardner, Mariko D Dewire, Christopher R Pierson, Randal Olshefski, Sandra A Rempel, Stewart Goldman, Lili Miles, Maryam Fouladi, Rachid Drissi.   

Abstract

Children with high-grade glioma, including diffuse intrinsic pontine glioma (DIPG), have a poor prognosis despite multimodal therapy. Identifying novel therapeutic targets is critical to improve their outcome. We evaluated prognostic roles of telomere maintenance mechanisms in children with HGG, including DIPG. A multi-institutional retrospective study was conducted involving 50 flash-frozen HGG (35 non-brainstem; 15 DIPG) tumors from 45 children (30 non-brainstem; 15 DIPG). Telomerase activity, expression of hTERT mRNA (encoding telomerase catalytic component) and TERC (telomerase RNA template) and alternative lengthening of telomeres (ALT) mechanism were assayed. Cox Proportional Hazard regression analyses assessed association of clinical and pathological variables, TERC and hTERT levels, telomerase activity, and ALT use with progression-free or overall survival (OS). High TERC and hTERT expression was detected in 13/28 non-brainstem HGG samples as compared to non-neoplastic controls. High TERC and hTERT expression was identified in 13/15 and 11/15 DIPG samples, respectively, compared to controls. Evidence of ALT was noted in 3/11 DIPG and 10/19 non-brainstem HGG specimens. ALT and telomerase use were identified in 4/19 non-brainstem HGG and 2/11 DIPG specimens. In multivariable analyses, increased TERC and hTERT levels were associated with worse OS in patients with non-brainstem HGG, after controlling for tumor grade or resection extent. Children with HGG and DIPG, have increased hTERT and TERC expression. In children with non-brainstem HGG, increased TERC and hTERT expression levels are associated with a worse OS, making telomerase a promising potential therapeutic target in pediatric HGG.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24477622      PMCID: PMC4261223          DOI: 10.1007/s11060-014-1374-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  51 in total

1.  Telomerase activation as a repair response to radiation-induced DNA damage in Y79 retinoblastoma cells.

Authors:  Masaharu Akiyama; Kohji Ozaki; Takeshi Kawano; Osamu Yamada; Kiyotaka Kawauchi; Hiroyuki Ida; Hisashi Yamada
Journal:  Cancer Lett       Date:  2013-07-11       Impact factor: 8.679

2.  Correlation of the expression of human telomerase subunits with telomerase activity in normal skin and skin tumors.

Authors:  A Wu; M Ichihashi; M Ueda
Journal:  Cancer       Date:  1999-11-15       Impact factor: 6.860

3.  Correlation of clinical features and telomerase activity in human gliomas.

Authors:  F Huang; H Kanno; I Yamamoto; Y Lin; Y Kubota
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

4.  Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues.

Authors:  C Poremba; C Scheel; B Hero; H Christiansen; K L Schaefer; J i Nakayama; F Berthold; H Juergens; W Boecker; B Dockhorn-Dworniczak
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

5.  Telomerase activity in human brain tumours.

Authors:  L A Langford; M A Piatyszek; R Xu; S C Schold; J W Shay
Journal:  Lancet       Date:  1995-11-11       Impact factor: 79.321

6.  The RNA component of human telomerase.

Authors:  J Feng; W D Funk; S S Wang; S L Weinrich; A A Avilion; C P Chiu; R R Adams; E Chang; R C Allsopp; J Yu
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

7.  Specific association of human telomerase activity with immortal cells and cancer.

Authors:  N W Kim; M A Piatyszek; K R Prowse; C B Harley; M D West; P L Ho; G M Coviello; W E Wright; S L Weinrich; J W Shay
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

8.  Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues.

Authors:  A A Avilion; M A Piatyszek; J Gupta; J W Shay; S Bacchetti; C W Greider
Journal:  Cancer Res       Date:  1996-02-01       Impact factor: 12.701

9.  Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis.

Authors:  M A Blasco; M Rizen; C W Greider; D Hanahan
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

10.  Telomerase activity in normal and malignant hematopoietic cells.

Authors:  D Broccoli; J W Young; T de Lange
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

View more
  16 in total

1.  A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.

Authors:  Ralph Salloum; Trent R Hummel; Shiva Senthil Kumar; Kathleen Dorris; Shaoyu Li; Tong Lin; Vinay M Daryani; Clinton F Stewart; Lili Miles; Tina Young Poussaint; Charles Stevenson; Stewart Goldman; Girish Dhall; Roger Packer; Paul Fisher; Ian F Pollack; Maryam Fouladi; James Boyett; Rachid Drissi
Journal:  J Neurooncol       Date:  2016-06-27       Impact factor: 4.130

2.  A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.

Authors:  Trent R Hummel; Ralph Salloum; Rachid Drissi; Shiva Kumar; Matthew Sobo; Stewart Goldman; Ahna Pai; James Leach; Adam Lane; David Pruitt; Mary Sutton; Lionel M Chow; Laurie Grimme; Renee Doughman; Lori Backus; Lili Miles; Charles Stevenson; Maryam Fouladi; Mariko DeWire
Journal:  J Neurooncol       Date:  2015-12-01       Impact factor: 4.130

3.  Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.

Authors:  Xiaogang Wang; Xiaoming Li; Feng Xu; Youqian Zhang; Hongwei Liu; Yingqun Tao
Journal:  Mol Neurobiol       Date:  2015-09-08       Impact factor: 5.590

4.  Commentary: Evaluating potential glioma serum biomarkers, with future applications.

Authors:  Michael Goutnik; Brandon Lucke-Wold
Journal:  World J Clin Oncol       Date:  2022-05-24

5.  hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.

Authors:  Gina Fürtjes; Michaela Köchling; Susanne Peetz-Dienhart; Andrea Wagner; Katharina Heß; Martin Hasselblatt; Volker Senner; Walter Stummer; Werner Paulus; Benjamin Brokinkel
Journal:  J Neurooncol       Date:  2016-07-27       Impact factor: 4.130

6.  ALTernative Telomere Maintenance and Cancer.

Authors:  Robert L Dilley; Roger A Greenberg
Journal:  Trends Cancer       Date:  2015-10-01

7.  Molecular Mechanism of Telomere Length Dynamics and Its Prognostic Value in Pediatric Cancers.

Authors:  Zhaoming Wang; Stephen V Rice; Ti-Cheng Chang; Yu Liu; Qi Liu; Na Qin; Daniel K Putnam; Kyla Shelton; Jennifer Q Lanctot; Carmen L Wilson; Kirsten K Ness; Michael C Rusch; Michael N Edmonson; Gang Wu; John Easton; Chimene A Kesserwan; James R Downing; Xiang Chen; Kim E Nichols; Yutaka Yasui; Leslie L Robison; Jinghui Zhang
Journal:  J Natl Cancer Inst       Date:  2020-07-01       Impact factor: 11.816

8.  Arsenic trioxide inhibits glioma cell growth through induction of telomerase displacement and telomere dysfunction.

Authors:  Ye Cheng; Yunqian Li; Chengyuan Ma; Yang Song; Haiyang Xu; Hongquan Yu; Songbai Xu; Qingchun Mu; Haisong Li; Yong Chen; Gang Zhao
Journal:  Oncotarget       Date:  2016-03-15

9.  Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics.

Authors:  Lindsey M Hoffman; Mariko DeWire; Scott Ryall; Pawel Buczkowicz; James Leach; Lili Miles; Arun Ramani; Michael Brudno; Shiva Senthil Kumar; Rachid Drissi; Phillip Dexheimer; Ralph Salloum; Lionel Chow; Trent Hummel; Charles Stevenson; Q Richard Lu; Blaise Jones; David Witte; Bruce Aronow; Cynthia E Hawkins; Maryam Fouladi
Journal:  Acta Neuropathol Commun       Date:  2016-01-04       Impact factor: 7.801

Review 10.  Telomere maintenance mechanisms in cancer: clinical implications.

Authors:  Roger R Reddel
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.